Slate Bio, Inc.

Slate Bio, Inc. focuses on developing innovative T regulatory therapies aimed at treating autoimmune diseases, restoring immune balance, and enhancing patient outcomes through targeted treatments. Founded in 2020 and headquartered in Charlottesville, US, Slate Bio, Inc. specializes in T regulatory therapies to address autoimmune diseases.

The company has completed 2 deals, with its most recent funding round being a Seed round in December 2022, raising USD 1. 35 mn, which matches the total amount raised of USD 1. 35 mn. The company was established by Michelle Higgin, who has a background in this sector.

Slate Bio, Inc. specializes in advanced T regulatory (T reg) therapies designed to address autoimmune diseases. The company's core offerings focus on restoring immune balance and promoting tolerance to self-antigens, ultimately aiming to reduce the symptoms and progression of autoimmune disorders. Slate Bio’s therapies are engineered to target specific pathways involved in immune dysregulation, making them suitable for a range of conditions.

These products are primarily marketed to healthcare providers and institutions involved in treating patients with autoimmune diseases, including hospitals, specialized clinics, and research facilities. The geographic markets for these products encompass North America and Europe, where the demand for innovative therapies in autoimmune disease management is growing. Slate Bio generates revenue through direct partnerships with healthcare providers and institutions, leveraging a business-to-business (B2B) model. This structure allows the company to supply its T reg therapies to hospitals and clinics that treat patients with autoimmune conditions.

Transactions typically occur on a contractual basis, where healthcare providers order products for use in treatment protocols and clinical research. Pricing structures for these proprietary therapies are aligned with industry standards for similar medical advancements, reflecting the innovative nature of the products. The focus on advanced, targeted treatments positions Slate Bio to serve both the immediate needs of patients and the long-term goals of healthcare providers in managing autoimmune diseases effectively. In December 2022, Slate Bio, Inc.

raised USD 1. 35 mn in Seed funding to support the development of new T reg therapies and expand market presence. The company plans to launch additional products designed specifically for various autoimmune diseases by 2024. Furthermore, Slate Bio aims to expand into new geographic markets, specifically targeting Asia and additional regions in Europe by late 2024 to meet the growing demand for effective autoimmune disease therapies.